- [Lorie] Advanced EvolutionBiotechnologies, or AEBI,

began its business in 2000.

Four years ago founderand CEO Dr. Ilan Morad

and his partner Dr. HananItzhaki started research

on a cure for cancer.

- We didn't want to have another drug

like everyone else that would give relief

to some cancer patients andthen the cancer would come back.

We wanted really to cure,something like antibiotics.

- The concept is basedon the same strategy used

to combat AIDS.

The patient is given a cocktail or mix

of medications designedto prevent the disease

from becoming resistant to any one drug.

- Because you know HIV isa very mitogenic creature,

same as cancer.

This is the problem with cancer

that it's very mitogenicand does mutations.

It helps the cancer escape the therapy.

- [Lorie] Here is this tinylab in Nes Ziona, Israel,

these two scientists cameup with a theory they hope

will cure cancer.

They call it MuTaTo.

That stands for Multi-Target Toxin.

- The main thing hereis multiple targeting.

Instead of attacking one target at a time,

we connect together several peptides

and we attack several targets at a time

and because of that, thecancer won't be able,

statistically won't beable to escape the therapy

and this is what happened with AIDS

and this is what willhappen here in cancer.

- [Lorie] And they pointout since this cocktail

specifically targets cancer cells,

it is not as harmful to healthy ones.

- The other thing is because

of this targeting peptidesare connected together,

and there's what we call affinity effect,

the side effects willbe much much much lower.

So it will be like an antibiotic.

- [Lorie] Morad says ifscientists could come up

with 100 different peptides,

they believe various combinations

could treat each kind of cancer.

- Each patient would get his own MuTaTo

that would fit perfectly his cancer.

He would have almost no side effects

and in no time, he wouldbe cured completely

because the cancer cellswould be completely killed,

every one of them.

- [Lorie] Morad saysthey have five peptides

in the pre-clinical stage.

When the article came out,

it basically caught themedical community by surprise

because AEBI's experimentshave been limited

and not published in medical journals.

CBN News approached Dr. Charles Guyer,

associate director for clinical research

as VCU Massey Cancer Center who was one

of many that urged caution.

He said, "We all hope that acure for cancer will be found,

"but cancer is a complexfamily of diseases

"and there's a history of similar claims

"that have unfortunately spread false hope

"to many patients and their loved ones.

"This news is based on limited information

"from the company and its researchers

"and the results from theirpre-clinical experiments

"have not been published

"in any peer-reviewed academic journals.

"I would approach this newswith healthy skepticism

"and also remind people thatit typically takes years

"to translate promisingpre-clinical research

"from the laboratory toevaluation in the clinic."

Morad said he wassurprised by the criticism.

- At least give me the credit.

Ask me what is the mechanism of our MuTaTo

or read carefully the firstarticle in the Jerusalem Post

to see what I really said.

- [Lorie] Morad said they need funding

to move their research

along faster and would like to collaborate

with larger pharmaceutical companies.

He also made clear theone goal on his mind.

- I don't care about the money.

I want to cure cancer patients.

- [Lorie] Lorie Johnson, CBN News.